This publication is a positive scientific milestone but does not change the binary risk of the Phase 3 ProstACT Global trial. Monitor for enrollment updates and interim data from the Phase 3 study, which will be the primary catalyst for TLX591-Tx's valuation. The historical win rate on TLX calls is low (22%), suggesting the market may already price in some optimism — avoid over-weighting this news.
Price Chart
Executive Summary
Telix announced peer-reviewed publication of ProstACT SELECT Phase 1 results in Cancers, confirming that 68Ga-PSMA-PET imaging can select patients for TLX591-Tx therapy. The data show a median radiographic progression-free survival of 8.8 months in evaluable patients, a manageable safety profile, and prolonged tumor retention. This is a positive scientific validation for TLX591-Tx's patient-selection strategy and supports the ongoing Phase 3 ProstACT Global trial, but does not change the binary regulatory or commercial outlook for the asset.
Key Facts
- ProstACT SELECT Phase 1 results published in peer-reviewed journal Cancers.
- Median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients.
- TLX591-Tx demonstrated manageable safety profile and prolonged tumor retention with low salivary gland irradiation.
- Publication supports patient-selection strategy for ongoing Phase 3 ProstACT Global trial in mCRPC.
Financial Impact
No financial figures disclosed; publication is scientific validation only.
Risk Factors
- Phase 3 ProstACT Global trial may fail to replicate efficacy or safety results.
- TLX591-Tx has not received marketing authorization in any jurisdiction; regulatory path is uncertain.
- Historical TLX reports show poor directional accuracy (22% win rate at T+20), indicating potential over-optimism in prior reads.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330996 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access